Date: 2016-01-27
Type of information: Nomination
Compound:
Company: Minoryx Therapeutics (Spain)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 27, 2016, Minoryx Therapeutics announced the appointment of Dr. Khalid Islam as chairman of the board of directors. Dr. Islam has 27 years experience in the pharmaceutical and biotechnology industries. Dr. Islam previously served as chairman and CEO of Gentium where he led the transition of the loss-making company to cash-flow positive and profitable. Under his leadership Defitelio® (defibrotide) was granted marketing authorization in the EU and the company’s value increased from $25 million to $1billion in a cash merger with Jazz Pharmaceuticals. From 1999-2008, he was president and CEO of Arpida AG where he transitioned the early-stage start-up to a SWX-listed company and raised $300M in the IPO and follow-ons. From 1987-1999, he held various positions in HMR & MMD (now Sanofi-Aventis). The appointment follows the €19.4 million series A fundraising that closed in October 2015. Dr. Khalid Islam succeeds Dr. Nigel Ten Fleming, who has been instrumental in the company’s success so far. Following the new appointment, Minoryx Therapeutics will move its lead candidate, MIN-102, into clinical stage. MIN-102 targets the most prevalent peroxisomal disorder, X-linked adrenoleukodystrophy (X-ALD). MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases and excellent in-vivo efficacy. Minoryx also plans to further develop SEE-Tx, a dedicated platform that relies on proprietary technology and know-how for the identification of a new class of pharmacological chaperones.
Financial terms:
Latest news:
